IDEXX Laboratories, Inc. $IDXX Shares Bought by SVB Wealth LLC

SVB Wealth LLC raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.4% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 7,335 shares of the company’s stock after buying an additional 1,089 shares during the period. SVB Wealth LLC’s holdings in IDEXX Laboratories were worth $4,121,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of IDXX. Beacon Investment Advisory Services Inc. boosted its holdings in IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after acquiring an additional 6,710 shares during the period. Nordea Investment Management AB increased its stake in IDEXX Laboratories by 114.1% during the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after purchasing an additional 8,845 shares during the period. Procyon Advisors LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth about $1,966,000. Diversified Trust Co. lifted its position in shares of IDEXX Laboratories by 223.5% during the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after purchasing an additional 2,901 shares in the last quarter. Finally, Mirabella Financial Services LLP lifted its position in shares of IDEXX Laboratories by 156.2% during the third quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock worth $2,806,000 after purchasing an additional 2,683 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IDXX. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. UBS Group dropped their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $545.73 on Tuesday. The firm has a market capitalization of $43.05 billion, a price-to-earnings ratio of 40.19, a PEG ratio of 3.07 and a beta of 1.56. The firm’s fifty day simple moving average is $560.88 and its 200-day simple moving average is $618.83. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.